Analyst Ratings for Orexigen Therapeutics (OREX)
OREX Rating Summary
OREX Price Target Summary
- Highest: $13.00 (Credit Suisse)
- Lowest: $5.00 (JMP Securities)
- Average: $9.29
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$9.29 (+44%)
Avg. $ Target:
$9.29 (+44%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/4/2013 | Piper Jaffray | New Coverage | Overweight (N/A) |
10.00 (N/A) |
5.82 | 6.45 | 10.82% | Details |
| 9/6/2012 | Credit Suisse | New Coverage | Outperform (N/A) |
13.00 (N/A) |
4.91 | 6.45 | 31.36% | Details |
| 7/16/2012 | Leerink Swann » Updated 7/18/2012 |
New Coverage | Outperform (N/A) |
12.00 (10.00) |
7.06 | 6.45 | -8.64% | Details |
| 6/28/2012 | JPMorgan » Updated 12/21/2012 |
Upgrade | Overweight (Neutral) |
12.00 (N/A) |
4.92 | 6.45 | 31.1% | Details |
| 3/12/2012 | BofA/Merrill Lynch | Upgrade | Buy (N/A) |
7.00 (N/A) |
3.70 | 6.45 | 74.32% | Details |
| 12/16/2011 | Lazard Capital | Upgrade | Neutral (N/A) |
N/A (N/A) |
1.51 | 6.45 | 327.15% | Details |
| 9/21/2011 | JMP Securities | Upgrade | Market Outperform (N/A) |
5.00 (N/A) |
1.47 | 6.45 | 338.78% | Details |
| 2/2/2011 | Jefferies » Updated 10/23/2012 |
Downgrade | Hold (N/A) |
6.00 (5.00) |
2.50 | 6.45 | 158% | Details |
| 2/1/2011 | Canaccord Genuity | Downgrade | Hold (N/A) |
N/A (N/A) |
2.52 | 6.45 | 155.95% | Details |
| 2/1/2011 | Cowen | Downgrade | Neutral (N/A) |
N/A (N/A) |
2.52 | 6.45 | 155.95% | Details |
| 12/3/2010 | Rodman & Renshaw | Downgrade | Market Underperform (N/A) |
N/A (N/A) |
5.47 | 6.45 | 17.92% | Details |
| 7/16/2010 | Davenport | Downgrade | Neutral (N/A) |
N/A (N/A) |
5.00 | 6.45 | 29% | Details |
